Tarsus posts Q2 2026 sales of $173.9M for XDEMVY
Tarsus reported Q2 2026 net product sales of $173.9 million for XDEMVY and updated full-year guidance to $685-705 million, while advancing a pending acquisition of Alkeus Pharmaceuticals.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day